Last updated on August 2018

An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) Injection in Kaposi Sarcoma (KS)

Brief description of study

To determine the safety of escalating doses of Tc 99m tilmanocept in HIV (human immunodeficiency virus) subjects with confirmed KS.

Detailed Study Description

This is a prospective, single-center, open-label, within-subject study of intravenously injected Tc 99m tilmanocept in the localization and detection of cutaneous and non-cutaneous KS tumor(s) in subjects with biopsy-confirmed KS. Six IV doses (g/mCi) of tilmanocept will be evaluated in cohort groups.

This study is designed to evaluate the safety and tolerability of escalating doses of Tc 99m tilmanocept. Whole body planar as well as SPECT/CT imaging will be performed to provide greater resolution of areas of Tc 99m tilmanocept localization. A biopsy of a non-visceral KS lesion will be taken to correlate pathology with Tc 99m tilmanocept localization.

This study is designed to evaluate the use of Tc 99m tilmanocept as an imaging agent in HIV-positive subjects with known KS by evaluating localization in known and unknown cutaneous and non-cutaneous lesions.

Clinical Study Identifier: NCT03157167

Contact Investigators or Research Sites near you

Start Over

Toby A Maurer, MD

Zuckerberg San Francisco General Hospital
San Francisco, CA United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.